Sagility has garnered attention as JPMorgan initiated an ‘Overweight’ rating on the stock with a target price of ₹54, implying an upside potential of 15.6% from its Current Market Price (CMP) of ₹46.73.
JPMorgan highlights Sagility’s niche focus on the healthcare sector, primarily catering to non-discretionary spending in the US healthcare market. The company is well-positioned to capitalize on secular tailwinds from increasing outsourcing in US healthcare, supported by its deep domain expertise and robust client relationships. This is expected to drive stable growth, even during economic fluctuations, due to its exposure to non-discretionary sectors.
Sagility’s high structural EBIT margins and strong fundamentals are projected to deliver an impressive 50% earnings CAGR over FY24-27, reinforcing investor confidence in the stock’s long-term growth trajectory.
Disclaimer: The information in this article is based on the brokerage report from JPMorgan and is intended for informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any stock. Investors are advised to conduct their own research or consult a professional financial advisor before making investment decisions.